Kraj: Kanada
Język: angielski
Źródło: Health Canada
MEDROXYPROGESTERONE ACETATE
TEVA CANADA LIMITED
G03DA02
MEDROXYPROGESTERONE
10MG
TABLET
MEDROXYPROGESTERONE ACETATE 10MG
ORAL
100/500/1000
Prescription
PROGESTINS
Active ingredient group (AIG) number: 0106339006; AHFS:
APPROVED
2011-01-18
PRODUCT MONOGRAPH PR TEVA-MEDROXYPROGESTERONE medroxyprogesterone acetate tablets USP 2.5 mg, 5 mg and 10 mg PROGESTIN Teva Canada Limited Date of Revision: 30 Novopharm Court May 12, 2014 Toronto, Ontario M1B 2K9 Control No: 173232 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 INDICATIONS AND CLINICAL USE...................................................................................... 3 CONTRAINDICATIONS ........................................................................................................... 4 WARNINGS AND PRECAUTIONS ......................................................................................... 5 ADVERSE REACTIONS ......................................................................................................... 14 DRUG INTERACTIONS .......................................................................................................... 16 DOSAGE AND ADMINISTRATION ...................................................................................... 18 OVERDOSAGE ........................................................................................................................ 20 ACTION AND CLINICAL PHARMACOLOGY .................................................................... 21 STORAGE AND STABILITY ................................................................................................. 24 DOSAGE FORMS, COMPOSITION AND PACKAGING ..................................................... 24 PART II: SCIENTIFIC INFORMATION ............................................................................... 25 PHARMACEUTICAL INFORMATION ................................................................................. 25 CLINICAL TRIALS.................................................................................................................. 26 DETAILED PHARMACOLOGY ............................................................................................. 28 TOXICOLOGY .............. Przeczytaj cały dokument